# Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

> **NCT05458674** · PHASE2 · RECRUITING · sponsor: **Criterium, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer
- Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer

## Interventions

- **DRUG:** Tucatinib
- **DRUG:** Eribulin
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT05458674
- **Lead sponsor:** Criterium, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-30
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05458674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05458674, "Tucatinib+Trastuzumab+Eribulin in HER2+ MBC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05458674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*